Expression and clinical significance of transmembrane protein 132A in liver cancer based on bioinformatics

Abstract

Abstract: Objective: To explore the expression pattern and clinical significance of transmembrane protein 132A (TMEM132A) in liver cancer based on public databases.
Methods: The Cancer Genome Atlas and GSE14520, GSE60502 of Gene Expression Omnibus was used to analyze the mRNA level of TMEM132A in liver cancer and adjacent tissues, the promoter methylation level, and the correlation with clinical factors. The immunohistochemical results of TMEM132A in tissues were obtained through HPA database. Kaplan-Meier method was used to explore the correlation between TMEM132A and the prognosis of patients. Receiver operating characteristic curve was used to explore whether TMEM132A could accurately diagnose patients. The drug sensitivity of TMEM132A to chemotherapy drugs was predicted by cancer drug sensitivity genomics. Immune analysis of TEME132A was performed by single-sample GSEA, TIMER, STORMAL SCORE and immune checkpoint heatmap. Linkedomics website was used to perform gene set enrichment analysis for differential genes of TMEM132A. The STRING database was used to predict the interacting proteins of TMEM132A.
Results: The expression of MEM132A in HCC tissues was significantly higher than that in adjacent tissues (P<0.05), and it was located in the cytoplasm and cell membrane. The high expression of TMEM132A was positively correlated with tumor stage, grade, AFP level and body weight. High expression of TMEM132A indicates poor prognosis and can be used as an accurate diagnostic indicator. TMEM132A is sensitive to a variety of chemotherapy drugs and infiltrated by a variety of immune cells, which can be used as a research target for drug therapy and immunotherapy. The promoter methylation level of TMEM132 was significantly decreased in cancer tissues. TMEM132A affects cell adhesion, fatty acid metabolism and other signaling pathways.
Conclusion: TMEM132A is highly expressed in HCC and positively correlated with poor prognosis.

Key words: Liver cancer, Transmembrane protein 132A, The cancer genome atlas

Zhao Hangqi, Ma Xiaowen, Zhang Tian'ai, Li Baifeng. Expression and clinical significance of transmembrane protein 132A in liver cancer based on bioinformatics[J]. Electronic Journal of Liver Tumor, 2024, 11(3): 33-41.

References

[1] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2022年版)[J/CD].肝癌电子杂志,2022,9(1):1-22.
[2] WEI W, JIAN P E, LI S H, et al.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety[J]. Cancer Commun (Lond), 2018, 38(1): 61.
[3] OH-HASHI K, IMAI K, KOGA H, et al.Knockdown of transmembrane protein 132A by RNA interference facilitates serum starvation-induced cell death in Neuro2a cells[J]. Mol Cell Biochem, 2010, 342(1-2): 117-123.
[4] GAO Q, CHEN Y, YUE L, et al.Knockdown of TMEM132A restrains the malignant phenotype of gastric cancer cells via inhibiting Wnt signaling[J]. Nucleosides Nucleotides Nucleic Acids, 2023, 42(5): 343-357.
[5] WU R, LI D, FENG D, et al.Transmembrane protein 132A (TMEM132A) predicts overall survival for bladder cancer patients[J]. Asian J Surg, 2023, 46(9): 3804-3806.
[6] ZHOU T, CAI Z, MA N, et al.A novel ten-gene signature predicting prognosis in hepatocellular carcinoma[J]. Front Cell Dev Biol, 2020, 8: 629.
[7] ZHOU T, CAI Z, MA N, et al.A novel ten-gene signature predicting prognosis in hepatocellular carcinoma[J]. Front Cell Dev Biol, 2020, 8: 629.
[8] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S, et al.UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649-658.
[9] CHANDRASHEKAR D S, KARTHIKEYAN S K, KORLA P K, et al.UALCAN: an update to the integrated cancer data analysis platform[J]. Neoplasia, 2022, 25: 18-27.
[10] MA X, FAN M, YANG K, et al.ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2[J]. Cancer Sci, 2023, 114(11): 4237-4251.
[11] JIN K, QIU S, JIN D, et al.Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database[J]. Aging (Albany NY), 2021, 13(2): 1859-1871.
[12] WANG J, SUN J, LIU L N, et al.Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4): 656-666.
[13] LI T, FU J, ZENG Z, et al.TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514.
[14] JIANG Q, SUN J, CHEN H, et al.Establishment of an immune cell infiltration score to help predict the prognosis and chemotherapy responsiveness of gastric cancer patients[J]. Front Oncol, 2021, 11: 650673.
[15] GREGERSEN N O, BUTTENSCHON H N, HEDEMAND A, et al.Are TMEM genes potential candidate genes for panic disorder?[J]. Psychiatr Genet, 2014, 24(1): 37-41.
[16] OH-HASHI K, NARUSE Y, AMAYA F, et al.Cloning and characterization of a novel GRP78-binding protein in the rat brain[J]. J Biol Chem, 2003, 278(12): 10531-10537.
[17] OH-HASHI K, HIRATA Y, KOGA H, et al.GRP78-binding protein regulates cAMP-induced glial fibrillary acidic protein expression in rat C6 glioblastoma cells[J]. FEBS Lett, 2006, 580(16): 3943-3947.
[18] ZHANG Y, ZHANG Z.The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J]. Cell Mol Immunol, 2020, 17(8): 807-821.
[19] RAMIREZ C, TARANTO D, ANDO-KURI M, et al.Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma[J]. Nat Commun, 2024, 15(1): 2581.
[20] CURRIE E, SCHULZE A, ZECHNER R, et al.Cellular fatty acid metabolism and cancer[J]. Cell Metab, 2013, 18(2): 153-161.
[21] LI Y, LI M, JIN F, et al.DNAJC12 promotes lung cancer growth by regulating the activation of beta-catenin[J]. Int J Mol Med, 2021, 47(6): 105.
[22] HUNG MC, YANG R, SUN Y.Powering tumor metastasis with recycled fuel[J]. Cancer Cell, 2016, 30(3): 374-375.